BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381-5387. [PMID: 17135639 DOI: 10.1200/jco.2006.06.5391] [Cited by in Crossref: 361] [Cited by in F6Publishing: 95] [Article Influence: 24.1] [Reference Citation Analysis]
Number Citing Articles
1 Kaidarova DR, Kopp MV, Pokrovsky VS, Dzhugashvili M, Akimzhanova ZM, Abdrakhmanov RZ, Babich EN, Bilan EV, Byakhov AV, Gurov SN, Koroleva IA, Mochalova AS, Povaga SS, Raigorodsky MV, Saifullin AS, Sanz E, Petrovskiy FI. Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy. Oncol Lett 2019;18:5644-52. [PMID: 31641390 DOI: 10.3892/ol.2019.10868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Okines DAF, Parton DM. De-escalation of adjuvant chemotherapy for HER2 negative breast cancer. Lancet Reg Health West Pac 2021;11:100177. [PMID: 34327370 DOI: 10.1016/j.lanwpc.2021.100177] [Reference Citation Analysis]
3 Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, Ruiz A, Weber KE, Munarriz B, Petry C, Rodriguez CA, Kronenwett R, Crespo C, Alba E, Carrasco E, Casas M, Caballero R, Rodriguez-Lescure A. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res 2014;16:R38. [PMID: 24725534 DOI: 10.1186/bcr3642] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 11.9] [Reference Citation Analysis]
4 Goyal RK, Tzivelekis S, Rothman KJ, Candrilli SD, Kaye JA. Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer. Support Care Cancer 2018;26:539-48. [PMID: 28921379 DOI: 10.1007/s00520-017-3863-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Sheng JY, Santa-Maria CA, Mangini N, Norman H, Couzi R, Nunes R, Wilkinson M, Visvanathan K, Connolly RM, Roussos Torres ET, Fetting JH, Armstrong DK, Tao JJ, Jacobs L, Wright JL, Thorner ED, Hodgdon C, Horn S, Wolff AC, Stearns V, Smith KL. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract 2020;16:665-74. [PMID: 32603252 DOI: 10.1200/OP.20.00364] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
6 Fenlon D, Powers C, Simmonds P, Clough J, Addington-Hall J. The JACS prospective cohort study of newly diagnosed women with breast cancer investigating joint and muscle pain, aches, and stiffness: pain and quality of life after primary surgery and before adjuvant treatment. BMC Cancer 2014;14:467. [PMID: 24964929 DOI: 10.1186/1471-2407-14-467] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
7 Qin YY, Li H, Guo XJ, Ye XF, Wei X, Zhou YH, Zhang XJ, Wang C, Qian W, Lu J, He J. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One 2011;6:e26946. [PMID: 22069477 DOI: 10.1371/journal.pone.0026946] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
8 Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Med 2019;8:5468-81. [PMID: 31361400 DOI: 10.1002/cam4.2423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Manchon P, Borràs JM, Ferro T, Espinàs JA; Breast Cancer OncoGuia Group. Breast Cancer OncoGuia. Clin Transl Oncol 2010;12:113-38. [PMID: 20156781 DOI: 10.1007/s12094-010-0477-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Younus J, Vandenberg T, Jawaid M, Jawaid MA. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis. Curr Oncol 2012;19:332-4. [PMID: 23300360 DOI: 10.3747/co.19.1174] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
11 Vandenberg T, Younus J, Al-Khayyat S. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol 2010;17:2-3. [PMID: 20404969 DOI: 10.3747/co.v17i2.498] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
12 Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE, Sparano JA. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012;30:3051-7. [PMID: 22851566 DOI: 10.1200/JCO.2011.39.8446] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
13 De Iuliis F, Salerno G, Giuffrida A, Milana B, Taglieri L, Rubinacci G, Giantulli S, Terella F, Silvestri I, Scarpa S. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation. Tumour Biol 2016;37:2603-11. [PMID: 26392111 DOI: 10.1007/s13277-015-4075-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
14 Kouroukis CT, Chia S, Verma S, Robson D, Desbiens C, Cripps C, Mikhael J. Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 2008;15:9-23. [PMID: 18317581 DOI: 10.3747/co.2008.198] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
15 Paluch-Shimon S, Cherny NI, de Vries EGE, Dafni U, Piccart MJ, Latino NJ, Cardoso F. Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. ESMO Open 2020;5:e000743. [PMID: 32893189 DOI: 10.1136/esmoopen-2020-000743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Alken S, Kelly CM. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res 2013;5:357-65. [PMID: 24143122 DOI: 10.2147/CMAR.S49321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yu KD, Liu XY, Chen L, Mo M, Wu J, Liu GY, Di GH, Verschraegen C, Stover DG, Zhuang ZG, Bertucci F, Orlandi A, Wang J, Lippi G, Wu KJ, Osman MA, Fan L, Shao ZM. Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. Lancet Reg Health West Pac 2021;11:100158. [PMID: 34327363 DOI: 10.1016/j.lanwpc.2021.100158] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yang Y, Yin Y, Zhang J, Zuo T, Liang X, Li J, Shen Q. Folate and Borneol Modified Bifunctional Nanoparticles for Enhanced Oral Absorption. Pharmaceutics 2018;10:E146. [PMID: 30181518 DOI: 10.3390/pharmaceutics10030146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
19 Leung M, Florendo J, Kano J, Marr-Del Monte T, Higgins B, Myers R, Menon T, Jones G. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer. Support Care Cancer 2015;23:1669-77. [PMID: 25421443 DOI: 10.1007/s00520-014-2449-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
20 Younis T, Rayson D, Skedgel C. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol 2011;18:e288-96. [PMID: 22184496 DOI: 10.3747/co.v18i6.810] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
21 Saibil S, Fitzgerald B, Freedman OC, Amir E, Napolskikh J, Salvo N, Dranitsaris G, Clemons M. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol 2010;17:42-7. [PMID: 20697513 DOI: 10.3747/co.v17i4.562] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
22 Lee YR, Park MS, Joo HK, Kim KM, Kim J, Jeon BH, Choi S. Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo. Sci Rep 2018;8:8701. [PMID: 29880821 DOI: 10.1038/s41598-018-27025-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. Support Care Cancer 2014;22:3275-85. [PMID: 25082364 DOI: 10.1007/s00520-014-2362-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
24 Saito Y, Takekuma Y, Kobayashi M, Sakamoto T, Yamashita H, Sugawara M. Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. Support Care Cancer 2021. [PMID: 34228171 DOI: 10.1007/s00520-021-06342-2] [Reference Citation Analysis]
25 Jones RL, Walsh G, Ashley S, Chua S, Agarwal R, O'Brien M, Johnston S, Smith IE. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009;100:305-10. [PMID: 19165198 DOI: 10.1038/sj.bjc.6604862] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
26 Gandhi S, Verma S. Early breast cancer in the older woman. Oncologist 2011;16:479-85. [PMID: 21415085 DOI: 10.1634/theoncologist.2010-0279] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
27 Ntellas P, Spathas N, Agelaki S, Zintzaras E, Saloustros E. Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. Oncotarget 2019;10:1209-16. [PMID: 30838092 DOI: 10.18632/oncotarget.26632] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
28 Fishman ML, Kumar A, Davis S, Shimp W, Hrushesky WJ. Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences. J Oncol Pract 2012;8:e14s-7s. [PMID: 22942828 DOI: 10.1200/JOP.2012.000540] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
29 Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2019;9:CD004421. [PMID: 31476253 DOI: 10.1002/14651858.CD004421.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
30 Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 2009;27:3430-6. [PMID: 19470942 DOI: 10.1200/JCO.2008.18.4085] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
31 Sharma P. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2018;19:22. [PMID: 29656345 DOI: 10.1007/s11864-018-0539-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
32 Mislang AR, Biganzoli L. Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? Cancers (Basel) 2015;7:1191-214. [PMID: 26151681 DOI: 10.3390/cancers7030833] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
33 Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol 2008;15:S16-29. [PMID: 18231644 DOI: 10.3747/co.2008.173] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
34 Bahl A, Singh R, Wadhwa J, Gupta S, Ahmed M, Uppal PN, Parikh PM, Aggarwal S. Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer. South Asian J Cancer 2018;7:102-5. [PMID: 29721473 DOI: 10.4103/sajc.sajc_111_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Yoo C, Kim SB, Ahn JH, Kim JE, Jung KH, Gong GY, Son BH, Ahn SH, Ahn SD, Kim HH, Shin HJ, Kim WK. A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. Cancer Res Treat 2015;47:406-15. [PMID: 25648092 DOI: 10.4143/crt.2014.073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
36 Younis T, Rayson D, Thompson K. Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer 2012;20:2523-30. [PMID: 22252548 DOI: 10.1007/s00520-011-1375-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
37 Kim SB, Kok YT, Thuan TV, Chao TY, Shen ZZ. Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II. J Breast Cancer 2015;18:356-64. [PMID: 26770242 DOI: 10.4048/jbc.2015.18.4.356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
38 Jin X, Jiang YZ, Chen S, Yu KD, Ma D, Sun W, Shao ZM, Di GH. A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer. BMC Cancer 2016;16:606. [PMID: 27495967 DOI: 10.1186/s12885-016-2652-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Barcenas CH, Zhang N, Zhao H, Duan Z, Buchholz TA, Hortobagyi GN, Giordano SH. Anthracycline regimen adherence in older patients with early breast cancer. Oncologist 2012;17:303-11. [PMID: 22371383 DOI: 10.1634/theoncologist.2011-0316] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
40 Thornton LM, Carson WE 3rd, Shapiro CL, Farrar WB, Andersen BL. Delayed emotional recovery after taxane-based chemotherapy. Cancer 2008;113:638-47. [PMID: 18521922 DOI: 10.1002/cncr.23589] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
41 Rack B, Andergassen U, Neugebauer J, Salmen J, Hepp P, Sommer H, Lichtenegger W, Friese K, Beckmann MW, Hauner D, Hauner H, Janni W. The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. Breast Care (Basel) 2010;5:395-400. [PMID: 21494405 DOI: 10.1159/000322677] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
42 Figueroa D, Asaduzzaman M, Young F. Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro. Biomed Res Int 2019;2019:6146972. [PMID: 30766885 DOI: 10.1155/2019/6146972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ribeiro J, Sousa B, Cardoso F. Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl 2013;11:3-22. [PMID: 26217109 DOI: 10.1016/j.ejcsup.2013.07.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer 2016;16:352. [PMID: 27259714 DOI: 10.1186/s12885-016-2385-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 15.0] [Reference Citation Analysis]
45 Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017;35:2647-55. [PMID: 28398846 DOI: 10.1200/JCO.2016.71.4147] [Cited by in Crossref: 109] [Cited by in F6Publishing: 50] [Article Influence: 27.3] [Reference Citation Analysis]
46 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
47 Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer 2015;23:3269-75. [PMID: 25933700 DOI: 10.1007/s00520-015-2731-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
48 Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31:2627-33. [PMID: 23733756 DOI: 10.1200/JCO.2012.44.8738] [Cited by in Crossref: 125] [Cited by in F6Publishing: 61] [Article Influence: 15.6] [Reference Citation Analysis]
49 Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092-9. [PMID: 18678836 DOI: 10.1200/JCO.2008.16.7841] [Cited by in Crossref: 74] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
50 Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, Hortobagyi GN, Smith BD, Giordano SH. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 2014;32:2010-7. [PMID: 24868022 DOI: 10.1200/JCO.2013.49.3676] [Cited by in Crossref: 75] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
51 Aribi A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, Toh M, Said JW, Koeffler HP. The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int J Cancer 2013;132:2730-7. [PMID: 23165325 DOI: 10.1002/ijc.27950] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
52 Chan A, Fu WH, Shih V, Coyuco JC, Tan SH, Ng R. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 2011;19:497-504. [PMID: 20232087 DOI: 10.1007/s00520-010-0843-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
53 Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015;23:1137-43. [PMID: 25576433 DOI: 10.1007/s00520-014-2597-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 6.7] [Reference Citation Analysis]
54 Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 2014;6:253-9. [PMID: 24904223 DOI: 10.2147/CMAR.S40601] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
55 Feng QJ, Zhang F, Huang XY, Wu ZX. Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis. Pathol Oncol Res 2014;20:179-84. [PMID: 23980023 DOI: 10.1007/s12253-013-9681-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
56 Jeon YW, Lim ST, Gwak H, Park SY, Shin J, Han HS, Suh YJ. Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy. Ann Surg Treat Res 2021;100:59-66. [PMID: 33585350 DOI: 10.4174/astr.2021.100.2.59] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Yang L, Zhang XC, Yu SF, Zhu HQ, Hu AP, Chen J, Shen P. Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. BMC Cancer 2015;15:917. [PMID: 26582454 DOI: 10.1186/s12885-015-1932-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
58 Tezuka K, Miura K, Nakano Y, Ueda T, Yagyu K, Matsuyama S, Shirai M, Okuda H, Ujikawa M, Ota T. Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer. World J Surg Oncol 2021;19:169. [PMID: 34116698 DOI: 10.1186/s12957-021-02289-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst 2018;110:669-76. [PMID: 29361042 DOI: 10.1093/jnci/djx259] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
60 Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann PU, Jírů-Hillmann S, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Baumgartner T, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching P, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Stangl S. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018;78:1056-88. [PMID: 30581198 DOI: 10.1055/a-0646-4630] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
61 Zaheed M, Wilcken N, Willson ML, O'Connell DL, Goodwin A. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev 2019;2:CD012873. [PMID: 30776132 DOI: 10.1002/14651858.CD012873.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
62 Lee YR, Kim KM, Jeon BH, Choi S. Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation. Oncotarget 2015;6:23383-98. [PMID: 26125438 DOI: 10.18632/oncotarget.4345] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
63 Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer 2009;45:561-71. [PMID: 19062268 DOI: 10.1016/j.ejca.2008.10.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
64 Batra A, Hannouf MB, Alsafar N, Lupichuk S. Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study. Breast 2020;54:1-7. [PMID: 32861882 DOI: 10.1016/j.breast.2020.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
65 Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 2012;17:900-9. [PMID: 22610153 DOI: 10.1634/theoncologist.2011-0442] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
66 Kimmick G. Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making. Curr Treat Options Oncol 2011;12:286-301. [PMID: 21638199 DOI: 10.1007/s11864-011-0159-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
67 Jensen BC, McLeod HL. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics 2013;14:205-13. [PMID: 23327580 DOI: 10.2217/pgs.12.205] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
68 Jolly TA, Williams GR, Bushan S, Pergolotti M, Nyrop KA, Jones EL, Muss HB. Adjuvant treatment for older women with invasive breast cancer. Womens Health (Lond). 2016;12:129-45; quiz 145. [PMID: 26767315 DOI: 10.2217/whe.15.92] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
69 Rayson D, Lutes S, Sellon M, Colwell B, Dorreen M, Drucker A, Jeyakumar A, Snow S, Younis T. Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study. Curr Oncol 2012;19:e216-8. [PMID: 22670112 DOI: 10.3747/co.19.940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
70 Clemons M, Mazzarello S, Hilton J, Joy A, Price-Hiller J, Zhu X, Verma S, Kehoe A, Ibrahim MF, Sienkiewicz M, Stober C, Vandermeer L, Hutton B, Mallick R, Fergusson D. Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). Support Care Cancer 2019;27:1345-54. [PMID: 30099602 DOI: 10.1007/s00520-018-4408-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer 2014;14:205-11. [PMID: 24342730 DOI: 10.1016/j.clbc.2013.10.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
72 Najafi S, Payandeh M, Sadeghi M, Shafaei V, Shojaiyan F, Abbasvandi F. Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial. Contemp Oncol (Pozn) 2017;21:83-9. [PMID: 28435404 DOI: 10.5114/wo.2017.66661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. Sci Rep 2021;11:7064. [PMID: 33782404 DOI: 10.1038/s41598-021-85962-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Sukauichai S, Pattarowas C. Melioidosis with Septic Shock and Disseminated Infection in a Neutropenic Patient Receiving Chemotherapy. Case Rep Infect Dis 2020;2020:8976180. [PMID: 32274228 DOI: 10.1155/2020/8976180] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Figueroa Gonzalez D, Young F. Gamma Tocopherol Reduced Chemotherapeutic-Induced ROS in an Ovarian Granulosa Cell Line, But Not in Breast Cancer Cell Lines In Vitro. Antioxidants (Basel) 2020;9:E51. [PMID: 31936058 DOI: 10.3390/antiox9010051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
76 Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O, Bailur JK, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem GE, Wildiers H. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget 2016;7:29977-88. [PMID: 27102154 DOI: 10.18632/oncotarget.8796] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
77 Jitawatanarat P, O'Connor TL, Kossoff EB, Levine EG, Chittawatanarat K, Ngamphaiboon N. Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. J Breast Cancer 2014;17:356-62. [PMID: 25548584 DOI: 10.4048/jbc.2014.17.4.356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
78 Hong J, Chen X, Huang J, Li C, Zhong L, Chen L, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Wan H, Shen K. Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. Integr Cancer Ther 2017;16:406-13. [PMID: 28818031 DOI: 10.1177/1534735416675952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
79 López-Tarruella S, Martín M. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 2009;11:204. [PMID: 19344489 DOI: 10.1186/bcr2226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
80 Gadisa DA, Assefa M, Tefera GM, Yimer G. Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study. J Oncol 2020;2020:2636514. [PMID: 32148494 DOI: 10.1155/2020/2636514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Hilton J, Vandermeer L, Sienkiewicz M, Mazzarello S, Hutton B, Stober C, Fergusson D, Blanchette P, Joy AA, Brianne Bota A, Clemons M. Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients. Support Care Cancer 2018;26:2323-31. [PMID: 29411131 DOI: 10.1007/s00520-018-4074-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
82 Shapiro CL. De-escalation yes, but not at the expense of efficacy: in defense of better treatment. NPJ Breast Cancer 2019;5:25. [PMID: 31428678 DOI: 10.1038/s41523-019-0120-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Bernard LM, Verma S, Thompson MF, Chan BC, Mittmann N, Asma L, Jones SE. A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735. Curr Oncol 2011;18:67-75. [PMID: 21505597 DOI: 10.3747/co.v18i2.701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
84 Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30:2232-2239. [PMID: 22614988 DOI: 10.1200/jco.2011.40.1273] [Cited by in Crossref: 118] [Cited by in F6Publishing: 57] [Article Influence: 13.1] [Reference Citation Analysis]
85 Cobb PW, Moon YW, Mezei K, Láng I, Bhat G, Chawla S, Hasal SJ, Schwartzberg LS. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study. Cancer Med 2020;9:6234-43. [PMID: 32687266 DOI: 10.1002/cam4.3227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
86 Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-92. [PMID: 19259090 DOI: 10.1038/sj.bjc.6604909] [Cited by in Crossref: 155] [Cited by in F6Publishing: 114] [Article Influence: 12.9] [Reference Citation Analysis]
87 Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M. Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer 2018;26:3073-81. [PMID: 29564623 DOI: 10.1007/s00520-018-4161-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
88 Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res 2009;15:7693-700. [PMID: 19996222 DOI: 10.1158/1078-0432.CCR-09-1450] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
89 Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, Wei C, Xia L, Junhua C. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics 2009;27:873-86. [PMID: 19803541 DOI: 10.2165/11314750-000000000-00000] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
90 Chaudhary LN. Early stage triple negative breast cancer: Management and future directions. Semin Oncol 2020;47:201-8. [PMID: 32507668 DOI: 10.1053/j.seminoncol.2020.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
91 Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol 2015;1:1311-8. [PMID: 26402167 DOI: 10.1001/jamaoncol.2015.3062] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
92 Schwartzberg LS, Bhat G, Peguero J, Agajanian R, Bharadwaj JS, Restrepo A, Hlalah O, Mehmi I, Chawla S, Hasal SJ, Yang Z, Cobb PW. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial. Oncologist 2020;25:e1233-41. [PMID: 32476162 DOI: 10.1634/theoncologist.2020-0105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013;108:1931-1935. [PMID: 23652302 DOI: 10.1038/bjc.2013.225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
94 Johnson R, Sabnis N, McConathy WJ, Lacko AG. The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics. 2013;5:353-370. [PMID: 24244833 DOI: 10.3390/pharmaceutics5020353] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
95 Ngamphaiboon N, O'Connor TL, Advani PP, Levine EG, Kossoff EB. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. Med Oncol 2012;29:1495-501. [PMID: 21818673 DOI: 10.1007/s12032-011-0035-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]